ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADMA ADMA Biologics

Pre-Market Trading 11-22 07:35:47 EST

21.30

-0.07

-0.33%

High21.70	Low20.87	Vol2.27M
Open21.60	D1 Closing21.37	Amplitude3.88%
Mkt Cap5.04B	Tradable Cap4.94B	Total Shares236.39M
T/O48.29M	T/O Rate0.98%	Tradable Shares232.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ADMA","market":"US","secType":"STK","nameCN":"ADMA Biologics","latestPrice":21.3,"timestamp":1732222800000,"preClose":21.37,"halted":0,"volume":2265386,"delay":0,"floatShares":231999999,"shares":236390253,"eps":0.280323,"marketStatus":"Pre-Market Trading","change":-0.07,"latestTime":"11-22 07:35:47 EST","open":21.6,"high":21.7,"low":20.87,"amount":48291715.889217995,"amplitude":0.038839,"askPrice":23.33,"askSize":100,"bidPrice":20.9,"bidSize":5,"shortable":3,"etf":0,"ttmEps":0.280323,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732285800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":21.3,"postHourTrading":{"tag":"盘后","latestPrice":21.4999,"preClose":21.3,"latestTime":"19:24 EST","volume":263951,"amount":5622158.471,"timestamp":1732235069804},"volumeRatio":0.8088694688124405,"impliedVol":0.4002,"impliedVolPercentile":0.1474},"requestUrl":"/m/hq/s/ADMA","defaultTab":"news","newsList":[{"id":"2484608051","title":"Wall Street Analysts See a 31.3% Upside in Adma Biologics (ADMA): Can the Stock Really Move This High?","url":"https://stock-news.laohu8.com/highlight/detail?id=2484608051","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484608051?lang=en_us&edition=fundamental","pubTime":"2024-11-18 22:55","pubTimestamp":1731941715,"startTime":"0","endTime":"0","summary":"Shares of Adma Biologics  have gained 20.7% over the past four weeks to close the last trading session at $19.04, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $25 indicates a potential upside of 31.3%.However, an impressive consensus price target is not the only factor that indicates a potential upside in ADMA. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nxwFIPS2ImeTQYZMYlnAgg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nxwFIPS2ImeTQYZMYlnAgg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-analysts-see-31-145515483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ADMA"],"gpt_icon":1},{"id":"2483304861","title":"Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet","url":"https://stock-news.laohu8.com/highlight/detail?id=2483304861","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483304861?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:30","pubTimestamp":1731681013,"startTime":"0","endTime":"0","summary":"Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed  analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about Adma Biologics  before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Adma Biologics currently has an average brokerage recommendation  of 1.00, on a scale of 1 to 5 , calculated based on the actual recommendations  made by four brokerage firms. An ABR of 1.00 indicates Strong Buy.Of the four recommendations that derive the current ABR, four are Strong Buy, representing 100% of all recommendations.The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every \"Strong Sell\" recommendation, brokerage firms ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kz0ozt3ejWMPXKci2JxOBw--~B/aD03NTQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kz0ozt3ejWMPXKci2JxOBw--~B/aD03NTQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brokers-suggest-investing-adma-biologics-143013069.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABR","BK4110","BK4139","ADMA"],"gpt_icon":0},{"id":"2483138321","title":"Statutory Profit Doesn't Reflect How Good ADMA Biologics' (NASDAQ:ADMA) Earnings Are","url":"https://stock-news.laohu8.com/highlight/detail?id=2483138321","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483138321?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:16","pubTimestamp":1731669386,"startTime":"0","endTime":"0","summary":"ADMA Biologics, Inc.'s  strong earnings report was rewarded with a positive stock price move. Our analysis found some more factors that we think are good for shareholders.NasdaqGM:ADMA Earnings and Revenue History November 15th 2024. To properly understand ADMA Biologics' profit results, we need to consider the US$29m expense attributed to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. If ADMA Biologics doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.Because unusual items detracted from ADMA Biologics' earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think ADMA Biologics' earnings po","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/statutory-profit-doesnt-reflect-good-111626983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","NDAQ","ADMA"],"gpt_icon":0},{"id":"2483080948","title":"ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?","url":"https://stock-news.laohu8.com/highlight/detail?id=2483080948","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483080948?lang=en_us&edition=fundamental","pubTime":"2024-11-12 22:15","pubTimestamp":1731420911,"startTime":"0","endTime":"0","summary":"Have you been paying attention to shares of Adma Biologics ?Shares have been on the move with the stock up 37.3% over the past month. The stock hit a new 52-week high of $23.64 in the previous session. Adma Biologics has gained 397.4% since the start of the year compared to the 4.7% move for the Zacks Medical sector and the 0.7% return for the Zacks Medical - Biomedical and Genetics industry.The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on November 7, 2024, Adma Biologics reported EPS of $0.15 versus consensus estimate of $0.13 while it beat the consensus revenue estimate by 11.74%.For the current fiscal year, Adma Biologics is expected to post earnings of $0.52 per share on $425.6 million in revenues. Meanwhile, for the next fiscal year, the company is expected to earn $0.77 per share on $492.67 million in revenues. This represents a year-over-year cha","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QOfludHza1dTKV8R6Coeiw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QOfludHza1dTKV8R6Coeiw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-inc-adma-hits-141511648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ADMA","BK4532","EXEL"],"gpt_icon":0},{"id":"2482730648","title":"Are Medical Stocks Lagging  Addex Therapeutics (ADXN) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2482730648","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482730648?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:40","pubTimestamp":1731336010,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Addex Therapeutics Ltd. Sponsored ADR  one of those stocks right now?Let's take a closer look at the stock's year-to-date performance to find out.Addex Therapeutics Ltd. Sponsored ADR is a member of the Medical sector. This group includes 1024 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Addex Therapeutics Ltd. Sponsored ADR is currently sporting a Zacks Rank of #2 .Addex Therapeutics Ltd. Sponsored ADR  : Free Stock Analysis Report","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fs_R4sd8jCoOMib958Znmg--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fs_R4sd8jCoOMib958Znmg--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-addex-therapeutics-144010072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADXN","ADMA","BK4139"],"gpt_icon":0},{"id":"2482259944","title":"Earnings Beat: Here's What ADMA Biologics, Inc. (NASDAQ:ADMA) Analysts Are Forecasting For Next Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2482259944","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482259944?lang=en_us&edition=fundamental","pubTime":"2024-11-09 21:42","pubTimestamp":1731159765,"startTime":"0","endTime":"0","summary":"ADMA Biologics, Inc.  just released its third-quarter report and things are looking bullish. It was a decent earnings report, with revenues and statutory earnings per share  both performing well. Revenues were 13% higher than the analysts had forecast, at US$120m, while EPS of US$0.15 beat analyst models by 15%. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around ADMA Biologics' earnings potential next year. They also upgraded their revenue forecasts, although the","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/earnings-beat-heres-adma-biologics-134245823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA",".IXIC","NDAQ"],"gpt_icon":0},{"id":"1163341506","title":"Stock Track | ADMA Biologics Surges on Record Q3 Performance and Raised Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1163341506","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163341506?lang=en_us&edition=fundamental","pubTime":"2024-11-09 05:05","pubTimestamp":1731099929,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc.  reported exceptional financial results for the third quarter of 2024, fueling a surge in its stock price. The biopharmaceutical company achieved record-breaking performance across key metrics, driven by strong demand for its flagship product, ASCENIV.Total revenue soared to $119.8 million, representing a remarkable 78% year-over-year increase. This robust top-line growth translated into a 256% surge in adjusted EBITDA, reaching $45.4 million. Furthermore, ADMA Biologics repo","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADMA"],"gpt_icon":0},{"id":"2482045378","title":"ADMA Biologics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2482045378","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482045378?lang=en_us&edition=fundamental","pubTime":"2024-11-09 05:00","pubTimestamp":1731099653,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc reports results for the quarter ended September 30 - Earnings SummaryADMA Biologics Inc ADMA.OQ reported quarterly adjusted earnings of 15 cents per share for the quarter ended Sept","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF3F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA"],"gpt_icon":0},{"id":"2482438527","title":"Q3 2024 ADMA Biologics Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2482438527","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482438527?lang=en_us&edition=fundamental","pubTime":"2024-11-09 01:19","pubTimestamp":1731086376,"startTime":"0","endTime":"0","summary":"Adam Grossman; President, Chief Executive Officer, Co-Founder, Interim Chief Financial Officer, Director; ADMA Biologics Inc. Brad Tade; Chief Financial Officer and Treasurer; ADMA Biologics Inc. Thank you for standing by. My name is Celine and I will be your conference operator today. At this time I would like to welcome everyone to the ADMA Biologics Financial Results Third Quarter 2024. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. I would now like to turn the call over to Skyler Bloom. Please go ahead.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q3-2024-adma-biologics-inc-171936863.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA"],"gpt_icon":0},{"id":"1110749872","title":"Stock Track | ADMA Biologics Stock Soars on Stellar Q3 Results and Raised Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1110749872","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110749872?lang=en_us&edition=fundamental","pubTime":"2024-11-08 22:47","pubTimestamp":1731077253,"startTime":"0","endTime":"0","summary":"Shares of ADMA Biologics  surged over 13% in pre-market trading today after the biopharmaceutical company reported record-breaking financial results for the third quarter of 2024. The company's stellar performance was fueled by strong demand for its flagship product, ASCENIV, which drove significant growth across key financial metrics.ADMA Biologics achieved total revenue of $119.8 million in Q3 2024, a remarkable 78% increase from the same period last year. This robust top-line growth translate","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADMA"],"gpt_icon":0},{"id":"2481417313","title":"ADMA Biologics Shares up 10.8% Premarket After Co Raises FY 2024 and 2025 Total Revenue Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2481417313","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481417313?lang=en_us&edition=fundamental","pubTime":"2024-11-08 19:44","pubTimestamp":1731066256,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL4N3MF1B2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADMA","BK4139"],"gpt_icon":0},{"id":"1186311013","title":"Stock Track | ADMA Biologics Soars in Pre-Market on Record Q3 Results and Robust Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1186311013","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186311013?lang=en_us&edition=fundamental","pubTime":"2024-11-08 17:18","pubTimestamp":1731057524,"startTime":"0","endTime":"0","summary":"ADMA Biologics  saw its stock surge over 8% in pre-market trading on Wednesday, fueled by the company's stellar third-quarter financial results and optimistic future outlook. The biopharmaceutical firm reported record revenue of $119.8 million, a staggering 78% increase year-over-year, while net income skyrocketed by an impressive 1,300% to $35.9 million.ADMA's robust performance was further evidenced by its adjusted EBITDA of $45.4 million, marking a 256% growth compared to the previous year. A","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADMA"],"gpt_icon":0},{"id":"2481815142","title":"ADMA Biologics Inc (ADMA) Q3 2024 Earnings Call Highlights: Record Revenue and Net Income Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2481815142","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481815142?lang=en_us&edition=fundamental","pubTime":"2024-11-08 15:28","pubTimestamp":1731050881,"startTime":"0","endTime":"0","summary":"Total Revenue: $119.8 million, a 78% increase year-over-year.Adjusted EBITDA: $45.4 million, a growth rate of 256% from the previous year.Net Income: $35.9 million, a 1,300% increase year-over-year.Gross Margin: 50% for the third quarter of 2024, compared to 37% in the third quarter of 2023.Operating Cash Flow: $25 million generated during the third quarter.Net Leverage Ratio: Improved to approximately 0.1x, annualizing the third quarter results.GuruFocus has detected 6 Warning Sign with ADMA.For the complete transcript of the earnings call, please refer to the full earnings call transcript.ADMA Biologics Inc  raised its financial guidance for 2024 and 2025, expecting total revenues to exceed $415 million and $465 million, respectively.The company faces challenges in securing enough high titer plasma to meet the growing demand for ASCENIV.Q: Can you provide more details on the potential for ASCENIV to become a $1 billion revenue opportunity and the efforts to increase hyperimmune plasm","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sAJi76aiBSVt7EuaxIOfdQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/e73e3b670441ba3be0e1723be76b8008","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sAJi76aiBSVt7EuaxIOfdQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/e73e3b670441ba3be0e1723be76b8008"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-inc-adma-q3-072801718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA"],"gpt_icon":0},{"id":"2481113593","title":"ADMA Biologics Reports Robust Q3 2024 Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2481113593","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481113593?lang=en_us&edition=fundamental","pubTime":"2024-11-08 13:19","pubTimestamp":1731043199,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc ( ($ADMA) ) has released its Q3 earnings. Here is a breakdown of the information ADMA Biologics Inc presented to its investors. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adma-biologics-reports-robust-q3-2024-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adma-biologics-reports-robust-q3-2024-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"2481216740","title":"Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481216740","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481216740?lang=en_us&edition=fundamental","pubTime":"2024-11-08 08:20","pubTimestamp":1731025204,"startTime":"0","endTime":"0","summary":"Adma Biologics  came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.Adma Biologics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $119.84 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 11.74%. This compares to year-ago revenues of $67.28 million. The company has topped consensus revenue estimates four times over the last four quarters.Adma Biologics shares have added about 335.2% since the beginning of the year versus the S&P 500's gain of 24.3%.While Adma Biologics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nxwFIPS2ImeTQYZMYlnAgg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nxwFIPS2ImeTQYZMYlnAgg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-adma-q3-earnings-002004540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA"],"gpt_icon":0},{"id":"2481167242","title":"Adma Biologics: Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2481167242","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481167242?lang=en_us&edition=fundamental","pubTime":"2024-11-08 07:17","pubTimestamp":1731021437,"startTime":"0","endTime":"0","summary":"RAMSEY, N.J.  — RAMSEY, N.J.  — Adma Biologics Inc.  on Thursday reported third-quarter net income of $35.9 million.On a per-share basis, the Ramsey, New Jersey-based company said it had profit of 15 cents.The infectious disease drug developer posted revenue of $119.8 million in the period.Adma Biologics shares have more than quadrupled since the beginning of the year. In the final minutes of trading on Thursday, shares hit $19.72, climbing fivefold in the last 12 months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-q3-earnings-snapshot-231717589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA"],"gpt_icon":0},{"id":"2481316876","title":"ADMA Biologics Q3 2024 GAAP EPS $0.15 Beats $0.11 Estimate, Sales $119.839M Beat $105.850M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481316876","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481316876?lang=en_us&edition=fundamental","pubTime":"2024-11-08 06:18","pubTimestamp":1731017909,"startTime":"0","endTime":"0","summary":"ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.11 by 36.36 percent.  The company reported quarterly sales of $119.839 million which beat the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41828097/adma-biologics-q3-2024-gaap-eps-0-15-beats-0-11-estimate-sales-119-839m-beat-105-850m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA"],"gpt_icon":0},{"id":"1155580951","title":"Stock Track | ADMA Biologics Surges After-Hours on Robust Q3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1155580951","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155580951?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:33","pubTimestamp":1731015181,"startTime":"0","endTime":"0","summary":"Shares of ADMA Biologics  soared by 5.48% in after-hours trading on Wednesday, November 7, 2024, following the company's impressive third-quarter financial results.The biopharmaceutical firm, focused on developing and manufacturing plasma-derived biologics, reported a remarkable net income of $35.9 million for the third quarter. Additionally, ADMA Biologics posted an adjusted EBITDA of $45.4 million and a robust gross margin of 50%.These strong financial figures, particularly the significant rev","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | ADMA Biologics Surges After-Hours on Robust Q3 Results","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ADMA"],"gpt_icon":0},{"id":"2481151086","title":"BRIEF-ADMA Biologics Q3 Revenue USD 119.8 Million Vs. IBES Estimate USD 105.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481151086","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481151086?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:05","pubTimestamp":1731013554,"startTime":"0","endTime":"0","summary":"Nov 07 (Reuters) - ADMA Biologics Q3 net income USD 35.9 million. * Q3 adjusted EBITDA USD 45.4 million * Q3 gross margin 50%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","USD"],"gpt_icon":0},{"id":"2481490151","title":"ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2481490151","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481490151?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:05","pubTimestamp":1731013510,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA8HWC45:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ADMA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.admabiologics.com","stockEarnings":[{"period":"1week","weight":0.0545},{"period":"1month","weight":0.3593},{"period":"3month","weight":0.1576},{"period":"6month","weight":1.228},{"period":"1year","weight":4.3924},{"period":"ytd","weight":3.7124}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.036203},{"month":2,"riseRate":0.5,"avgChangeRate":-0.013938},{"month":3,"riseRate":0.6,"avgChangeRate":0.097898},{"month":4,"riseRate":0.6,"avgChangeRate":0.007327},{"month":5,"riseRate":0.7,"avgChangeRate":0.076004},{"month":6,"riseRate":0.2,"avgChangeRate":-0.053782},{"month":7,"riseRate":0.7,"avgChangeRate":0.113035},{"month":8,"riseRate":0.3,"avgChangeRate":0.011317},{"month":9,"riseRate":0.2,"avgChangeRate":-0.020319},{"month":10,"riseRate":0.4,"avgChangeRate":-0.051308},{"month":11,"riseRate":0.6,"avgChangeRate":0.086481},{"month":12,"riseRate":0.4,"avgChangeRate":-0.05303}],"exchange":"NASDAQ","name":"ADMA Biologics","nameEN":"ADMA Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ADMA Biologics,ADMA,ADMA Biologics股票,ADMA Biologics股票老虎,ADMA Biologics股票老虎国际,ADMA Biologics行情,ADMA Biologics股票行情,ADMA Biologics股价,ADMA Biologics股市,ADMA Biologics股票价格,ADMA Biologics股票交易,ADMA Biologics股票购买,ADMA Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction